Navigation Links
Ireland Cancer Center researchers advance stem cell gene therapy
Date:12/12/2007

A-MGMT gene.

In addition to this promising research, Ireland Cancer Center scientists presented 24 oral and poster presentations at ASH. The breadth and depth of this innovative hematologic research at the Ireland Cancer Center are outstanding, says Alvin Schmaier, MD, Chief of Hematology/Oncology at UHCMC and Case Western Reserve University School of Medicine. Our faculty is making tremendous advances in these fields which is reflected in their being chosen for oral and poster presentations.

The presentations include:

  • Dr. Hillard Lazarus and colleagues presented significant findings that treatment with Rituximab before transplantation results in cure rate and overall survival in patients undergoing autologous stem cell transplantation for Diffuse Large B-Cell lymphoma.

  • Dr. Lazarus and colleagues of the Eastern Cooperative Oncology Group (ECOG) presented data that show that Imatninib (Gleevec) does not change outcomes on patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

  • Dr. Lazarus presented an assessment of data over 30 years regarding acute leukemia and its management. He found that all avenues lead to stem cell transplantations. His team provided this assessment of a whole host of entities that provide leukemia care.

  • Dr. Jonathan Kenyon and colleagues found that normal individuals over age 50 begin to show evidence that genetic mutations are accumulating in marrow stem cells. This finding might be the key underlying the increased risk of anemias, myelodysplastic syndrome and acute leukemia in older individuals.

  • Dr. Kevin Buntings laboratory gave two important presentations on how intracellular STAT5 (an intracellular signaling protein) influences normal pathologic hematopoiesis (blood cell formation) and stem cell engraftment.

  • Dr. Shigemi Matsuyama and colleagues presented a nov
    '/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals of Cleveland
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related biology news :

1. Green tea boosts production of detox enzymes, rendering cancerous chemicals harmless
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. ESF EURYI award winner aims to stop cancer cells reading their own DNA
4. Protein chatter linked to cancer activation
5. Newly created cancer stem cells could aid breast cancer research
6. Western diet linked to increased risk of colon cancer recurrence
7. Obesity and lack of exercise could enhance the risk of pancreatic cancer
8. Low levels of key protein may indicate pancreatic cancer risk
9. Birth records hold pancreatic cancer clue
10. Many parents at-risk for cancer disclose genetic test results to children
11. A new radiation therapy treatment developed for head and neck cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... children understand that green plants photosynthesize, absorb carbon ... profound global-scale effects that photosynthesis has had on ... the origins and evolution of photosynthesis is Jeffrey ... of Life Sciences. , Oxygen, one of the ... and their descendants (including algae and higher plants), ...
(Date:12/11/2009)... nearly two decades, Ivy Pike, an associate professor of ... ethnic groups in rural northern Kenya to understand how ... living there. , The results of her and her ... in three pastoralist communities of northern Kenya: A conceptual ... Social Science and Medicine , in collaboration with ...
(Date:12/11/2009)... December 11, 2009 Keystone Symposia on ... the appointment of five new Keystone Symposia Fellows ... enables five talented early-career life scientists (postdoctoral trainees ... program development process for one year. Fellows are ... as a commitment to promoting diversity in the ...
Breaking Biology News(10 mins):'Extreme' genes shed light on origins of photosynthesis 2'Extreme' genes shed light on origins of photosynthesis 3UA-led study grapples with health effects of low-intensity warfare 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 2Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 3Keystone Symposia appoints 5 Fellows as part of diversity in life science initiative 4Reportlinker Adds World Botulinum Toxin Market Report 56773 1Reportlinker Adds World Botulinum Toxin Market Report 56773 2Reportlinker Adds World Botulinum Toxin Market Report 56773 3Reportlinker Adds World Botulinum Toxin Market Report 56773 4Reportlinker Adds World Botulinum Toxin Market Report 56773 5Reportlinker Adds World Botulinum Toxin Market Report 56773 6Reportlinker Adds World Botulinum Toxin Market Report 56773 7Reportlinker Adds World Botulinum Toxin Market Report 56773 8Reportlinker Adds World Botulinum Toxin Market Report 56773 9Reportlinker Adds World Botulinum Toxin Market Report 56773 10Reportlinker Adds World Botulinum Toxin Market Report 56773 11Reportlinker Adds World Botulinum Toxin Market Report 56773 12Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 1Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 2Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 3Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 4Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 5Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 6Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 7Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 8Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 9Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 10Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 11Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 12Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 13Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 14Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 15Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 16Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 17Reportlinker Adds US and European Radiopharmaceuticals Market Report 56769 18Groups are key to good health 56765 1Groups are key to good health 56765 2Groups are key to good health 56765 3
... with lead partner Women & Infants Hospital of Rhode ... expand its participation in the National Children,s Study, a ... The National Institute of Child Health and Human Development ... the National Institutes of Health, announced the award today. ...
... A UC Riverside-led team of biomedical scientists has found ... treat acne and skin infections, can be used to treat ... of mental impairment and the most common cause of autism. ... the approval of a new clinical trial in Toronto, Canada, ...
... his State of the Union Address on January 23, 2007, ... oil imports, "We must increase the supply of alternative fuels, ... gallons of renewable and alternative fuels in 2017." , ... in the 2008 Farm Bill and a $45 subsidy per ...
Other Biology News:Brown University and Women & Infants Hospital expand national children's study to Bristol County 2Brown University and Women & Infants Hospital expand national children's study to Bristol County 3Brown University and Women & Infants Hospital expand national children's study to Bristol County 4UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 2UCR researchers propose minocycline as a promising drug for patients with Fragile X syndrome 3Mandate for biofuels production requires science-based policy and global perspective 2
(Date:12/11/2009)... 11 Ambit Biosciences Corporation announced today the ... D. Anderson Cancer Center of the first patient in ... E fficacy) Phase 2 pivotal trial in ... AC220 is a novel, orally available, potent and ... a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE ...
(Date:12/11/2009)... PA December 11, 2009 -- Esco announces the opening of a ... serve as a technical service, training and logistics center to support ... of New Product Introductions (NPI) for temperature-controlled laboratory equipment. , ... ... the opening of a NEW 2nd North American facility in Marietta, ...
(Date:12/10/2009)... the economy and markets exhibiting continued signs of growth, ... equity research provider, will seek to educate investors on ... cap market at the firm,s First 2010 Micro ... Grand Hyatt Hotel in New York, NY. ... much of Wall Street, but the well-informed investor has ...
(Date:12/10/2009)... CORALVILLE, Iowa, Dec. 10 Vivakor, ... that it has entered into an exclusive, ... specialist, Regeneca International, Inc. ( www.regeneca.com ). ... distribution rights to a new cutting-edge nutraceutical ... the development of future formulations by Vivakor ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3
... its revolutionary Trusted LASIK Eye Surgeons directory service ... . What sets the Trusted LASIK Surgeons directory ... only the best LASIK Surgeons in the United ... LASIK Surgeon Dr. R. Wayne Bowman, are screened ...
... Therapeutics, Inc., a,biotechnology company focused on the ... poorly controlled inflammation, announced today,the successful completion ... and pharmacokinetics study of LT-NS001, the Company,s ... from December, 2007,through July, 2008 in normal ...
... LifeVantage Corporation,(OTC Bulletin Board: LFVN), the maker of Protandim(R), ... of aging, today announced,that the company,s President & CEO, ... 3-Minute Press Show., The interview gives viewers an ... latest press release., To view ...
Other Biology Technology:Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 2Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 3Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 4Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 5Trusted LASIK Surgeons Welcomes Dallas LASIK Eye Surgery Specialist Dr. R. Wayne Bowman to its LASIK Directory 6Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug 2[video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.net's 3-Minute Press Show 2
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
PKA Sampler Kit 10 mu g each...
DNA Repair Sampler Kit 10g each...
Biology Products: